Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics

Lexicon Pharmaceuticals, Inc. (LXRX): $1.75

0.03 (+1.74%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add LXRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#319 of 349

in industry

LXRX Price/Volume Stats

Current price $1.75 52-week high $3.73
Prev. close $1.72 52-week low $0.92
Day low $1.69 Volume 2,516,700
Day high $1.80 Avg. volume 3,801,250
50-day MA $1.76 Dividend yield N/A
200-day MA $1.67 Market Cap 430.91M

LXRX Stock Price Chart Interactive Chart >


Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio


Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.


LXRX Latest News Stream


Event/Time News Detail
Loading, please wait...

LXRX Latest Social Stream


Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Yahoo | December 26, 2023

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place January 8 – January 12, 2024. Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation at 10:30am PT / 1:30 pm ET on Thursday, January 11th. Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, an

Yahoo | December 21, 2023

MSCLF: AAK1 Disclosed as Drug Target for DMD Program…

By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update AAK1 Disclosed as Drug Target for DMD Program On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced that AAK1 is the drug target for the company’s Duchenne muscular dystrophy (DMD) program, that SAT-3247 has been nominated as the lead drug candidate, and that IND-enabling studies and GMP

Yahoo | December 13, 2023

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in more than 20 years LX9211 has previously received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DPNP THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRE

Yahoo | November 30, 2023

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Cr

Yahoo | November 22, 2023

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo -1.13%
3-mo -27.39%
6-mo 33.59%
1-year -25.85%
3-year -62.28%
5-year -70.54%
YTD 14.38%
2023 -19.90%
2022 -51.52%
2021 15.20%
2020 -17.59%
2019 -37.50%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!